期刊文献+

微量右美托咪啶对罗哌卡因硬膜外麻醉效果的影响 被引量:9

在线阅读 下载PDF
导出
摘要 目的研究硬膜外麻醉时,在罗哌卡因溶液中复合微量右美托咪啶对硬膜外麻醉效果的影响。方法将82例ASAⅠ~Ⅱ级行下肢或输尿管镜手术患者,随机分为4组,R组为对照组:0.75%罗哌卡因15 mL+1 mL生理盐水硬膜外注射;D1组:0.75%罗哌卡因15 mL+2μg右美托咪啶硬膜外注射;D2组:0.75%罗哌卡因15 mL+4μg右美托咪啶硬膜外注射;D3组:0.75%罗哌卡因15 mL+8μg右美托咪啶硬膜外注射。监测记录注药后0、5、10、15、20、30、40、60、120 min患者心率、平均血压(MBP)以及感觉和运动阻滞的起效和恢复时间。结果与R组相比,D2和D3组感觉阻滞起效时间均缩短,D1、D2、D3组运动阻滞起效时间均缩短(P均<0.05);D2组感觉和运动阻滞维持时间延长(P均<0.05)。D3组在注药后40、60 min MBP下降明显(P均<0.05)。结论复合微量右美托咪啶可以增强罗哌卡因硬膜外麻醉效果,右美托咪啶最佳剂量是4μg。
出处 《山东医药》 CAS 2013年第1期76-78,共3页 Shandong Medical Journal
  • 相关文献

参考文献8

  • 1Kanazi GE, Aouad MT, Jabbour-Khoury SI, et al. Effect of low dose dexmedetomidine or clonidine on the characteristics of bupiva caine spinal block [ J ]. Acta Anaesthesiol Scand, 2006,50 ( 2 ) 222 -227.
  • 2李民,张利萍,吴新民.右美托咪啶在临床麻醉中应用的研究进展[J].中国临床药理学杂志,2007,23(6):466-470. 被引量:483
  • 3Gcntili M, Juhcl A, Bonnet F. Peripheral analgesic effect of intra- artlicular clonidine [ J ]. Pain, 1996,64 ( 3 ) :593-596.
  • 4Yaksh TL. Pharmacology of spinal adrenergic systems which modu- late spinal nociceptive processing[ J ]. Pharmacol Biochem Behav, 1985,22 ( 5 ) : 845 -858.
  • 5Mensink FJ, Kozody R, Kehler CH, et al. Dose-response relation- ship of ehmidine in tetracaine spinal anesthesia[ J ]. Anesthesiolo- gy, 1987,67(5) :717-721.
  • 6Klimscha W, Chiari A, Kraffl P, et al. Hemodynamic and analgesic effects of clonidine added repetitively to continuous epidural and spi- nal blocks[ J ]. Anesth Analg, 1995,80 (2) :322-327.
  • 7Niemi L. Efib+cts of intrathecal clonidine on duration of bupivacaine spinal anaesthesia, haemodynamics, and postoperative analgesia in patients undergoing knee arthroscopy[J] Acta AnaesthesioL Stand, 1994,38(7 ) :724-728.
  • 8Butterworth JF 5th, Strichartz GR. The alpha 2-adrenergie agonists clunidine and guanfacine produce tonic and phasic block of conduc- tion in rat sciatic nerve fibers [ J ]. Anesth Analg, 1993,76 ( 2 ) :295-301.

二级参考文献39

  • 1[1]Khan ZP,Ferguson CN,Jones RM.Alpha-2 and imidazoline receptor agonists:their pharmacology and therapeutic role[J].Anesthesia,1999;54:146-165.
  • 2[2]Kamibayashi T,Maze M.Clinical uses of alpha 2-adrenergic agonists[J].Anesthesiology,2000;93:1345-1350.
  • 3[3]Calzada BC,De Artinano AA.[alpha]2-Adrenoreceptor subtypes[J].Pharmacol Res,2001;44:195-208.
  • 4[4]Hunter JC,Fontanna DJ,Hedley LR,et al.Assessment of the role of alpha 2-adrenoceptor subtypes in the antinociceptive,sedative and hypothermic action of dexmedetomidine in transgenic mice[J].Br J Pharmacol,1997;122:1339-1344.
  • 5[5]Nelson LE,Lu J,Guo TZ,et al.The α2-Adrenoceptor agonist dexmedetomidine converges on an endogenous sleep-promoting pathway to exert its sedative effects[J].Anesthesiology,2003;98:428-436.
  • 6[6]Coull JT,Jones M,Egan T,et al.Attentionla effects of noradranaline vary with arousal level:selective activation of thalamie pulvinar in humans[J].Neuro Image,2004;22:315-322.
  • 7[7]Eisenach JC.[Alpha]2 agonists and analgesia[J].Exp Opin Invest Drugs,1994;3:1005-1010.
  • 8[8]Ma D,Rajakumamswamy N,Maze M.Alpha2-Adrenoceptor agonists:shedding light on neuroprotection?[J].Br Med Bull,2005;71:77-92.
  • 9[9]Ebert TJ,Hall JE,Barney JA,et al.The effects of increasing plasma concentrations of dexmedetomidine in humans[J].Anesthesiology,2000;93:382-394.
  • 10[10]Ramsey MA,Luterman DL.Dexmedetomidine as a total intravenous anesthestic agent[J].Anesthesiology,2004;101:787-781.

共引文献482

同被引文献54

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部